Northwest Biotherapeutics, Inc. (BST:NBYB)

Northwest Biotherapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-82.32	-83.78	-62.6	-105.03	179.13	-529.82
Depreciation & Amortization	2.04	2.04	1.73	1.5	0.59	0.43
Other Amortization	2.27	2.48	2.37	2.77	2.3	3.01
Stock-Based Compensation	1.89	3.46	4.41	12.3	15.5	52.21
Other Operating Activities	14.46	8.78	4.14	28.48	-238.54	442.12
Change in Accounts Payable	16.81	9.85	-4.43	6.85	-0.6	2.13
Change in Other Net Operating Assets	0.33	0.16	0.73	0.36	3.32	-2.17
Operating Cash Flow	-44.52	-57.02	-53.64	-52.78	-38.3	-32.09
Capital Expenditures	-0.65	-1.01	-3.44	-2.9	-6.02	-6.61
Cash Acquisitions	-	-	-	-	-	-1.53
Investing Cash Flow	-0.65	-1.01	-3.44	-2.9	-6.02	-8.14
Short-Term Debt Issued	-	0.2	0.01	2.57	0.25	0.32
Long-Term Debt Issued	-	34.02	33.34	5.6	29.67	13.67
Total Debt Issued	29.62	34.22	33.35	8.17	29.92	13.99
Short-Term Debt Repaid	-	-	-	-	-	-0.38
Long-Term Debt Repaid	-	-1.43	-0.39	-5.49	-5.83	-1.65
Total Debt Repaid	-1.98	-1.43	-0.39	-5.49	-5.83	-2.02
Net Debt Issued (Repaid)	27.65	32.78	32.96	2.68	24.09	11.96
Issuance of Common Stock	23.83	15.75	1.72	20.57	24.05	40.73
Other Financing Activities	-	0.05	4.75	-	-	0
Financing Cash Flow	51.74	56.79	52.76	41.97	48.13	52.7
Foreign Exchange Rate Adjustments	-5.14	1.3	-0.52	5.51	1.37	-2.85
Net Cash Flow	1.44	0.05	-4.84	-8.2	5.19	9.61
Free Cash Flow	-45.17	-58.03	-57.07	-55.68	-44.31	-38.7
Free Cash Flow Margin	-4128.98%	-4199.06%	-2954.14%	-3308.20%	-4409.35%	-2997.91%
Free Cash Flow Per Share	-0.03	-0.05	-0.05	-0.06	-0.04	-0.05
Cash Interest Paid	0.34	0.13	0.06	0.91	1.73	0.04
Levered Free Cash Flow	-23.79	-30.19	-118.13	-44.98	-270	325.19
Unlevered Free Cash Flow	-21.06	-27.81	-117.23	-43.96	-269.17	327.52
Change in Working Capital	17.14	10	-3.7	7.21	2.73	-0.04

Source: S&P Global Market Intelligence. Standard template. Financial Sources.